Checkpoint Therapeutics, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
Fortress Biotech, a significant shareholder and director, has fully divested its holdings in Checkpoint Therapeutics following the company's acquisition by Sun Pharmaceutical Industries for $4.10 per share plus a contingent value right.
Checkpoint Therapeutics, Inc. Director and 10% owner Michael S. Weiss has disposed of all his common stock holdings, totaling 187,007 shares, as part of a merger agreement for $4.10 cash per share plus a contingent value right.
Checkpoint Therapeutics Director Barry M. Salzman has disposed of all his common stock holdings, totaling 147,007 shares, in connection with the previously announced merger agreement, receiving $4.10 per share in cash plus a contingent value right.
Form 4: Checkpoint Therapeutics Director Sells Shares in Merger, Receives Cash and Contingent Value Rights
Checkpoint Therapeutics Director Lindsay A. Rosenwald MD disposed of 207,007 shares of common stock in connection with a merger agreement, receiving $4.10 per share in cash and one contingent value right per share.
Checkpoint Therapeutics' CEO, James F. Oliviero III, has disposed of 3,759,929 shares of common stock in connection with a previously announced merger agreement, receiving $4.10 cash per share plus a contingent value right.
A director of Checkpoint Therapeutics, Neil Herskowitz, has disposed of all his shares in the company as part of a previously announced merger agreement, receiving cash and contingent value rights.
Checkpoint Therapeutics' Chief Financial Officer, William Garrett Gray, has disposed of over 1.4 million shares of common stock in connection with the company's merger agreement, receiving cash and contingent value rights tied to future European regulatory approval of cosibelimab.
Christian Bechon, a Director at Checkpoint Therapeutics, Inc., has disposed of all his common stock holdings in connection with the previously announced merger agreement, receiving cash and contingent value rights.
A director of Checkpoint Therapeutics, Amit Sharma, disposed of 94,246 shares of common stock in connection with the previously announced merger agreement, receiving $4.10 cash per share plus a contingent value right.
Checkpoint Therapeutics CEO James Oliviero sold 15,090 shares of common stock on April 2, 2025, to cover tax withholding obligations related to the vesting of restricted shares.
William Garrett Gray, CFO of Checkpoint Therapeutics, sold 12,322 shares of common stock on April 1, 2025, to cover tax withholding obligations related to vesting restricted shares.
Fortress Biotech, a 10% owner of Checkpoint Therapeutics, acquired 18,500 shares of common stock as an equity fee related to a financing consummated by Checkpoint.
CEO James Oliviero sold shares of Checkpoint Therapeutics stock to cover tax obligations related to the vesting of restricted shares.
William Garrett Gray, CFO of Checkpoint Therapeutics, sold shares to cover tax obligations related to vesting restricted stock.
Checkpoint Therapeutics' Chief Financial Officer, William Garrett Gray, acquired 500,000 shares of restricted stock on January 30, 2025.
Checkpoint Therapeutics CEO, James F. Oliviero III, was granted 1.5 million restricted shares of common stock, vesting over three years.
Fortress Biotech, a significant shareholder in Checkpoint Therapeutics, acquired additional shares through equity fee grants related to financing activities and an annual equity fee.
Checkpoint Therapeutics CEO, James F. Oliviero III, sold shares to cover tax obligations and transferred shares to an irrevocable trust for his children.
Checkpoint Therapeutics' Chief Financial Officer, William Garrett Gray, sold 268,432 shares of common stock to cover tax obligations related to vesting restricted stock.
Michael S. Weiss, a director at Checkpoint Therapeutics, acquired 12,638 shares of common stock following the achievement of a corporate milestone.
A Checkpoint Therapeutics director, Barry M. Salzman, acquired 17,638 shares of common stock following the achievement of a corporate milestone.
Director Lindsay A. Rosenwald acquired 12,638 shares of Checkpoint Therapeutics stock following the achievement of a corporate milestone.
Checkpoint Therapeutics CEO, James F. Oliviero III, acquired 2,077,700 shares of common stock following the achievement of a corporate milestone, increasing his total holdings to 4,016,980 shares.
Checkpoint Therapeutics' Chief Financial Officer, William Garrett Gray, acquired 629,000 shares of common stock following the achievement of a corporate milestone.
A Checkpoint Therapeutics director, Christian Bechon, acquired 14,994 shares of common stock following the achievement of a corporate milestone.
Director Neil Herskowitz acquired 17,638 shares of Checkpoint Therapeutics stock following the achievement of a corporate milestone.
Fortress Biotech, a 10% owner of Checkpoint Therapeutics, acquired 146,341 shares of common stock as an equity fee following the closing of a financing.
CEO James Oliviero sold shares to cover tax obligations related to vesting restricted stock and transferred shares to an irrevocable trust for his children.
William Garrett Gray, CFO of Checkpoint Therapeutics, sold 13,038 shares of common stock on June 26, 2024, to cover tax obligations related to vesting restricted stock.
William Garrett Gray, CFO of Checkpoint Therapeutics, acquired 540,000 shares of restricted common stock on May 24, 2024, as part of a vesting schedule.